The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Multicenter Trial of a Combination Probiotic for Children with Gastroenteritis
Open accessAbstract
BACKGROUND: Gastroenteritis accounts for approximately 1.7 million visits to the emergency department (ED) by children in the United States every year. Data to determine whether the use of probiotics improves outcomes in these children are lacking. METHODS: colony-forming units twice daily or placebo. The primary outcome was moderate-to-severe gastroenteritis, which was defined according to a post-enrollment modified Vesikari scale symptom score of 9 or higher (scores range from 0 to 20, with higher scores indicating more severe disease). Secondary outcomes included the duration of diarrhea and vomiting, the percentage of children who had unscheduled physician visits, and the presence or absence of adverse events. RESULTS: Moderate-to-severe gastroenteritis within 14 days after enrollment occurred in 108 of 414 participants (26.1%) who were assigned to probiotics and 102 of 413 participants (24.7%) who were assigned to placebo (odds ratio, 1.06; 95% confidence interval [CI], 0.77 to 1.46; P=0.72). After adjustment for trial site, age, detection of rotavirus in stool, and frequency of diarrhea and vomiting before enrollment, trial-group assignment did not predict moderate-to-severe gastroenteritis (odds ratio, 1.06; 95% CI, 0.76 to 1.49; P=0.74). There were no significant differences between the probiotic group and the placebo group in the median duration of diarrhea (52.5 hours [interquartile range, 18.3 to 95.8] and 55.5 hours [interquartile range, 20.2 to 102.3], respectively; P=0.31) or vomiting (17.7 hours [interquartile range, 0 to 58.6] and 18.7 hours [interquartile range, 0 to 51.6], P=0.18), the percentages of participants with unscheduled visits to a health care provider (30.2% and 26.6%; odds ratio, 1.19; 95% CI, 0.87 to 1.62; P=0.27), and the percentage of participants who reported an adverse event (34.8% and 38.7%; odds ratio, 0.83; 95% CI, 0.62 to 1.11; P=0.21). CONCLUSIONS: In children who presented to the emergency department with gastroenteritis, twice-daily administration of a combined L. rhamnosus-L. helveticus probiotic did not prevent the development of moderate-to-severe gastroenteritis within 14 days after enrollment. (Funded by the Canadian Institutes of Health Research and others; PROGUT ClinicalTrials.gov number, NCT01853124 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
Besselink, M. G., van Santvoort, H. C., Buskens, E., Boermeester, M. A., van Goor, H., Timmerman, H. M., Nieuwenhuijs, V. B., Bollen, T. L., van Ramshorst, B., Witteman, B. J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60207-x · Cited by 1,367
Guarino, A., Ashkenazi, S., Gendrel, D., Lo Vecchio, A., Shamir, R., & Szajewska, H. (2014) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000375 · Cited by 935
A randomized synbiotic trial to prevent sepsis among infants in rural India
Panigrahi, P., Parida, S., Nanda, N. C., Satpathy, R., Pradhan, L., Chandel, D. S., Baccaglini, L., Mohapatra, A., Mohapatra, S. S., Misra, P. R., et al. (2017) · Nature · doi:10.1038/nature23480 · Cited by 526
Saccharomyces cerevisiae Fungemia: An Emerging Infectious Disease
Munoz, P., Bouza, E., Cuenca-Estrella, M., Eiros, J. M., Perez, M. J., Sanchez-Somolinos, M., Rincon, C., Hortal, J., & Pelaez, T. (2005) · Clinical Infectious Diseases · doi:10.1086/429916 · Cited by 462
Modulation of rotavirus severe gastroenteritis by the combination of probiotics and prebiotics
Gonzalez-Ochoa, G., Flores-Mendoza, L. K., Icedo-Garcia, R., Gomez-Flores, R., & Tamez-Guerra, P. (2017) · Archives of Microbiology · doi:10.1007/s00203-017-1400-3 · Cited by 82
Ringel-Kulka, T., McRorie, J., & Ringel, Y. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.511 · Cited by 31
Freedman, S. B., Sherman, P. M., Willan, A., Johnson, D., Gouin, S., Schuh, S., & (PERC), O. B. O. P. E. R. C. (2015) · Clinical Pediatrics · doi:10.1177/0009922815569200 · Cited by 16
Self-citation
Cited by
The pros, cons, and many unknowns of probiotics
Suez, J., Zmora, N., Segal, E., & Elinav, E. (2019) · Nature Medicine · doi:10.1038/s41591-019-0439-x · Cited by 1,398
Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2 Diabetes
Scheithauer, T. P. M., Rampanelli, E., Nieuwdorp, M., Vallance, B. A., Verchere, C. B., van Raalte, D. H., & Herrema, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.571731 · Cited by 673
Gut barrier disruption and chronic disease
Martel, J., Chang, S.-H., Ko, Y.-F., Hwang, T.-L., Young, J. D., & Ojcius, D. M. (2022) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2022.01.002 · Cited by 514
Next-generation sequencing: insights to advance clinical investigations of the microbiome
Wensel, C. R., Pluznick, J. L., Salzberg, S. L., & Sears, C. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154944 · Cited by 437
Harnessing the microbiome to prevent global biodiversity loss
Peixoto, R. S., Voolstra, C. R., Sweet, M., Duarte, C. M., Carvalho, S., Villela, H., Lunshof, J. E., Gram, L., Woodhams, D. C., Walter, J., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01173-1 · Cited by 269
The microbiome in inflammatory bowel diseases: from pathogenesis to therapy
Liu, S., Zhao, W., Lan, P., & Mou, X. (2021) · Protein & Cell · doi:10.1007/s13238-020-00745-3 · Cited by 263
Montassier, E., Valdés-Mas, R., Batard, E., Zmora, N., Dori-Bachash, M., Suez, J., & Elinav, E. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00920-0 · Cited by 256
Reappraisal of probiotics’ safety in human
Sotoudegan, F., Daniali, M., Hassani, S., Nikfar, S., & Abdollahi, M. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.04.032 · Cited by 154
Probiotics for treating acute infectious diarrhoea
Collinson, S., Deans, A., Padua-Zamora, A., Gregorio, G. V., Li, C., Dans, L. F., & Allen, S. J. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003048.pub4 · Cited by 153
Use of Probiotics for the Management of Acute Gastroenteritis in Children: An Update
Szajewska, H., Guarino, A., Hojsak, I., Indrio, F., Kolacek, S., Orel, R., Salvatore, S., Shamir, R., van Goudoever, J. B., Vandenplas, Y., et al. (2020) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002751 · Cited by 90
Huang, R., Xing, H.-Y., Liu, H.-J., Chen, Z.-F., & Tang, B.-B. (2021) · Translational Pediatrics · doi:10.21037/tp-21-511 · Cited by 48
Patro-Gołąb, B., & Szajewska, H. (2019) · Nutrients · doi:10.3390/nu11112762 · Cited by 49
Mourey, F., Sureja, V., Kheni, D., Shah, P., Parikh, D., Upadhyay, U., Satia, M., Shah, D., Troise, C., & Decherf, A. (2020) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002849 · Cited by 33
Liu, K., Zhang, Z., Su, Y., Ma, X., Wang, J., Yang, Q., Nie, Q., Mo, Z., Zhou, H., Zouboulis, C. C., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04291-8 · Cited by 2
Metadata
- Authors
- Freedman, S. B., Williamson-Urquhart, S., Farion, K. J., Gouin, S., Willan, A. R., Poonai, N., Hurley, K., Sherman, P. M., Finkelstein, Y., Lee, B. E., Pang, X.-L., Chui, L., Schnadower, D., Xie, J., Gorelick, M., & Schuh, S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-22
- Volume
- 379
- Issue
- 21
- Pages
- 2015-2026
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2901521492
- Cited by
- 234
- References
- 8
- FWCI
- 27.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.